195 related articles for article (PubMed ID: 19233181)
21. Genetic variants of UGT1A6 influence risk of colorectal adenoma recurrence.
Hubner RA; Muir KR; Liu JF; Logan RF; Grainge M; Armitage N; Shepherd V; Popat S; Houlston RS;
Clin Cancer Res; 2006 Nov; 12(21):6585-9. PubMed ID: 17085674
[TBL] [Abstract][Full Text] [Related]
22. Genotypes of the cytochrome p450 isoform, CYP2C9, and the vitamin K epoxide reductase complex subunit 1 conjointly determine stable warfarin dose: a prospective study.
Carlquist JF; Horne BD; Muhlestein JB; Lappé DL; Whiting BM; Kolek MJ; Clarke JL; James BC; Anderson JL
J Thromb Thrombolysis; 2006 Dec; 22(3):191-7. PubMed ID: 17111199
[TBL] [Abstract][Full Text] [Related]
23. Interindividual variability in ibuprofen pharmacokinetics is related to interaction of cytochrome P450 2C8 and 2C9 amino acid polymorphisms.
García-Martín E; Martínez C; Tabarés B; Frías J; Agúndez JA
Clin Pharmacol Ther; 2004 Aug; 76(2):119-27. PubMed ID: 15289789
[TBL] [Abstract][Full Text] [Related]
24. Linking pharmacovigilance with pharmacogenetics.
Clark DW; Donnelly E; Coulter DM; Roberts RL; Kennedy MA
Drug Saf; 2004; 27(15):1171-84. PubMed ID: 15588114
[TBL] [Abstract][Full Text] [Related]
25. Functional impact of CYP2C95, CYP2C96, CYP2C98, and CYP2C911 in vivo among black Africans.
Allabi AC; Gala JL; Horsmans Y; Babaoglu MO; Bozkurt A; Heusterspreute M; Yasar U
Clin Pharmacol Ther; 2004 Aug; 76(2):113-8. PubMed ID: 15289788
[TBL] [Abstract][Full Text] [Related]
26. Cytochrome P450 2C9 phenotyping using low-dose tolbutamide.
Jetter A; Kinzig-Schippers M; Skott A; Lazar A; Tomalik-Scharte D; Kirchheiner J; Walchner-Bonjean M; Hering U; Jakob V; Rodamer M; Jabrane W; Kasel D; Brockmöller J; Fuhr U; Sörgel F
Eur J Clin Pharmacol; 2004 May; 60(3):165-71. PubMed ID: 15045499
[TBL] [Abstract][Full Text] [Related]
27. Clinical consequences of cytochrome P450 2C9 polymorphisms.
Kirchheiner J; Brockmöller J
Clin Pharmacol Ther; 2005 Jan; 77(1):1-16. PubMed ID: 15637526
[TBL] [Abstract][Full Text] [Related]
28. Quantitative assessment of the effect of cytochrome P450 2C9 gene polymorphism and colorectal cancer.
Zhao Y; Han Y; Zhang L; Wang Y; Ma Y; Zhang F; Fu D; Wang X
PLoS One; 2013; 8(4):e60607. PubMed ID: 23577132
[TBL] [Abstract][Full Text] [Related]
29. Influence of CYP2C9 genotype on warfarin dose requirements--a systematic review and meta-analysis.
Lindh JD; Holm L; Andersson ML; Rane A
Eur J Clin Pharmacol; 2009 Apr; 65(4):365-75. PubMed ID: 19031075
[TBL] [Abstract][Full Text] [Related]
30. Association between cytochrome P450 2C9 gene polymorphisms and colorectal cancer susceptibility: evidence from 16 case-control studies.
Wang H; Ren L; He Y; Wei Y; Chen Z; Yang W; Fu Y; Xu X; Fu W; Hu G; Lou W
Tumour Biol; 2014 May; 35(5):4317-22. PubMed ID: 24414392
[TBL] [Abstract][Full Text] [Related]
31. Epoxide hydrolase and CYP2C9 polymorphisms, cigarette smoking, and risk of colorectal carcinoma in the Nurses' Health Study and the Physicians' Health Study.
Tranah GJ; Chan AT; Giovannucci E; Ma J; Fuchs C; Hunter DJ
Mol Carcinog; 2005 Sep; 44(1):21-30. PubMed ID: 15924351
[TBL] [Abstract][Full Text] [Related]
32. CYP2C9 and UGT1A6 genotypes modulate the protective effect of aspirin on colon adenoma risk.
Bigler J; Whitton J; Lampe JW; Fosdick L; Bostick RM; Potter JD
Cancer Res; 2001 May; 61(9):3566-9. PubMed ID: 11325819
[TBL] [Abstract][Full Text] [Related]
33. [Cytochrome P450 2C9 polymorphisms (CYP2C9) and warfarin maintenance dose in elderly patients].
Siguret V; Gouin I; Golmard JL; Geoffroy S; Andreux JP; Pautas E
Rev Med Interne; 2004 Apr; 25(4):271-4. PubMed ID: 15050794
[TBL] [Abstract][Full Text] [Related]
34. CYP2C9 genotypes and dose requirements during the induction phase of oral anticoagulant therapy.
Peyvandi F; Spreafico M; Siboni SM; Moia M; Mannucci PM
Clin Pharmacol Ther; 2004 Mar; 75(3):198-203. PubMed ID: 15001971
[TBL] [Abstract][Full Text] [Related]
35. Design and baseline characteristics of participants in a phase III randomized trial of celecoxib and selenium for colorectal adenoma prevention.
Thompson P; Roe DJ; Fales L; Buckmeier J; Wang F; Hamilton SR; Bhattacharyya A; Green S; Hsu CH; Chow HH; Ahnen DJ; Boland CR; Heigh RI; Fay DE; Martinez ME; Jacobs E; Ashbeck EL; Alberts DS; Lance P
Cancer Prev Res (Phila); 2012 Dec; 5(12):1381-93. PubMed ID: 23060037
[TBL] [Abstract][Full Text] [Related]
36. Pharmacogenetics of acenocoumarol: cytochrome P450 CYP2C9 polymorphisms influence dose requirements and stability of anticoagulation.
Tàssies D; Freire C; Pijoan J; Maragall S; Monteagudo J; Ordinas A; Reverter JC
Haematologica; 2002 Nov; 87(11):1185-91. PubMed ID: 12414349
[TBL] [Abstract][Full Text] [Related]
37. Influence of CYP2C9 and CYP2C19 genetic polymorphisms on warfarin maintenance dose and metabolic clearance.
Scordo MG; Pengo V; Spina E; Dahl ML; Gusella M; Padrini R
Clin Pharmacol Ther; 2002 Dec; 72(6):702-10. PubMed ID: 12496751
[TBL] [Abstract][Full Text] [Related]
38. Warfarin and celecoxib interaction in the setting of cytochrome P450 (CYP2C9) polymorphism with bleeding complication.
Malhi H; Atac B; Daly AK; Gupta S
Postgrad Med J; 2004 Feb; 80(940):107-9. PubMed ID: 14970301
[TBL] [Abstract][Full Text] [Related]
39. Distribution of the major cytochrome P450 (CYP) 2C9 genetic variants in a Saudi population.
Mirghani RA; Chowdhary G; Elghazali G
Basic Clin Pharmacol Toxicol; 2011 Aug; 109(2):111-4. PubMed ID: 21371265
[TBL] [Abstract][Full Text] [Related]
40. Celecoxib for the Prevention of Colorectal Adenomas: Results of a Suspended Randomized Controlled Trial.
Thompson PA; Ashbeck EL; Roe DJ; Fales L; Buckmeier J; Wang F; Bhattacharyya A; Hsu CH; Chow SH; Ahnen DJ; Boland CR; Heigh RI; Fay DE; Hamilton SR; Jacobs ET; Martinez EM; Alberts DS; Lance P
J Natl Cancer Inst; 2016 Dec; 108(12):. PubMed ID: 27530656
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
